Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology.
Biomarkers
Cardiovascular prevention
Cardiovascular risk
Diabetes mellitus
Heart failure
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
21
05
2022
received:
15
11
2021
accepted:
13
06
2022
pubmed:
16
6
2022
medline:
26
7
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Knowledge on risk predictors of incident heart failure (HF) in patients with type 2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognized as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established cardiovascular biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and cardiovascular events in patients with T2D and in those with established HF and T2D.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1162-1170Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 European Society of Cardiology.
Références
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853-72.
Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39:4243-54.
Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, et al. Heart failure end points in cardiovascular outcome trials of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a critical evaluation of clinical and regulatory issues. Circulation. 2019;140:2108-18.
Farmakis D, Butler J, Filippatos G. Sodium-glucose co-transporter 2 inhibitors: ‘a tale of two sisters’, diabetes and heart failure. Eur J Heart Fail. 2020;22:1259-62.
Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al.; ESC-HFA HF Long-Term Registry Investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54-65.
Johansson I, Dahlström U, Edner M, Näsman P, Rydén L, Norhammar A. Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018;15:494-503.
Varela-Roman A, Grigorian Shamagian L, Barge Caballero E, Mazon Ramos P, Rigueiro Veloso P, Gonzalez-Juanatey JR. Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study. Eur J Heart Fail. 2005;7:859-64.
Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28:1081-91.
Kodama S, Fujihara K, Horikawa C, Sato T, Iwanaga M, Yamada T, et al. Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2020;7:2146-74.
Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, et al. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol. 2018;250:188-94.
Zareini B, Rørth R, Holt A, Mogensen UM, Selmer C, Gislason G, et al. Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol. 2019;18:79.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
Honigberg MC, Zekavat SM, Pirruccello JP, Natarajan P, Vaduganathan M. Cardiovascular and kidney outcomes across the glycemic spectrum: insights from the UK Biobank. J Am Coll Cardiol. 2021;78:453-64.
Lund LH, Hage C, Savarese G. Implementation science and potential for screening in heart failure. Eur Heart J. 2022;43:413-5.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-31.
Watson C, James S, O'Connell E, Gallagher J, O'Reilly J, Tallon E, et al. Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. Biomarkers. 2016;21:538-43.
Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, et al. Clinical and biomarker predictors of expanded heart failure outcomes in patients with type 2 diabetes mellitus after a recent acute coronary syndrome: insights from the EXAMINE trial. J Am Heart Assoc. 2020;9:e012797.
Ohkuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al.; ADVANCE Collaborative Group. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial. Diabetes Care. 2017;40:1203-9.
Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, et al. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. Diabetes Obes Metab. 2019;21:736-40.
Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, et al. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2020;19:180.
Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, et al. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021;23:1026-36.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-88.
Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, et al.; EXAMINE Investigators. Relation of serum and urine renal biomarkers to cardiovascular risk in patients with type 2 diabetes mellitus and recent acute coronary syndromes (from the EXAMINE trial). Am J Cardiol. 2019;123:382-91.
Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Tigas S, Makriyiannis D, et al. Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus. Clin Biochem. 2018;53:31-7.
Tonkonogi A, Carlsson AC, Helmersson-Karlqvist J, Larsson A, Ärnlöv J. Associations between urinary kidney injury biomarkers and cardiovascular mortality risk in elderly men with diabetes. Ups J Med Sci. 2016;121:174-8.
Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439-50.
Ärnlöv J, Sang Y, Ballew SH, Vaidya D, Michos ED, Jacobs DR, et al. Endothelial dysfunction and the risk of heart failure in a community-based study: the Multi-Ethnic Study of Atherosclerosis. ESC Heart Fail. 2020;7:4231-40.
Néri AK, da S Junior GB, Meneses GC, Mc Martins A, De F Daher E, da C Lino DO, et al. Cardiovascular risk assessment and association with novel biomarkers in patients with type 2 diabetes mellitus. Biomark Med. 2021;15:561-76.
Natarajan A, Marshall SM, Kesteven PJ, McComb JM, Rutter MK. Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in type 2 diabetes. Diabet Med. 2011;28:1201-5.
Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Östling G, et al.; SUMMIT Consortium. Use of vascular assessments and novel biomarkers to predict cardiovascular events in type 2 diabetes: the SUMMIT VIP study. Diabetes Care. 2018;41:2212-9.
Cournot M, Burillo E, Saulnier PJ, Planesse C, Gand E, Rehman M, et al. Circulating concentrations of redox biomarkers do not improve the prediction of adverse cardiovascular events in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2018;7:e007397.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
Echouffo-Tcheugui JB, Kaze AD, Fonarow GC, Dagogo-Jack S. Severe hypoglycemia and incident heart failure among adults with type 2 diabetes. J Clin Endocrinol Metab. 2022;107:e955-62.
Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the Atherosclerosis Risk in Communities study. Diabetes. 2010;59:2020-6.
Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008;51:2197-204.
Blecker S, Park H, Katz SD. Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovasc Disord. 2016;16:99.
Shin SH, Claggett B, Pfeffer MA, Skali H, Liu J, Aguilar D, et al.; ELIXA Investigators. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. Eur J Heart Fail. 2020;22:1133-43.
Luk AOY, Ma RCW, Lau ESH, Yang X, Lau WWY, Yu LWL, et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2013;29:384-90.
Gu J, Pan JA, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus. Cardiovasc Diabetol. 2018;17:96.
McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, et al.; TECOS Study Group. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. Eur J Heart Fail. 2020;22:2026-34.
Liu JE, Robbins DC, Palmieri V, Bella JN, Roman MJ, Fabsitz R, et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol. 2003;41:2022-8.
Cheung N, Wang JJ, Rogers SL, Brancati F, Klein R, Sharrett AR, et al.; ARIC (Atherosclerosis Risk in Communities) Study Investigators. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol. 2008;51:1573-8.
Fraty M, Velho G, Gand E, Fumeron F, Ragot S, Sosner P, et al.; SURDIAGENE Study Group. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study. Diabetologia. 2018;61:2643-53.
Markova A, Boyanov M, Bakalov D, Kundurdjiev A, Tsakova A. Cardiovascular biomarkers and calculated cardiovascular risk in orally treated type 2 diabetes patients: is there a link? Horm Metab Res. 2021;53:41-8.
Bielska A, Niemira M, Kretowski A. Recent highlights of research on miRNAs as early potential biomarkers for cardiovascular complications of type 2 diabetes mellitus. Int J Mol Sci. 2021;22:3153.
Al-Hayali MA, Sozer V, Durmus S, Erdenen F, Altunoglu E, Gelisgen R, et al. Clinical value of circulating microribonucleic acids miR-1 and miR-21 in evaluating the diagnosis of acute heart failure in asymptomatic type 2 diabetic patients. Biomolecules. 2019;9:193.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-4.
de Gonzalo-Calvo D, van der Meer RW, Rijzewijk LJ, Smit JWA, Revuelta-Lopez E, Nasarre L, et al. Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci Rep. 2017;7:47.
Bijkerk R, Esguerra JLS, Ellenbroek JH, Au YW, Hanegraaf MAJ, de Koning EJ, et al. In vivo silencing of microRNA-132 reduces blood glucose and improves insulin secretion. Nucleic Acid Ther. 2019;29:67-72.
Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178-88.
Pandey A, Vaduganathan M, Patel KV, Ayers C, Ballantyne CM, Kosiborod MN, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9:215-23.
van der Leeuw J, Beulens JWJ, van Dieren S, Schalkwijk CG, Glatz JFC, Hofker MH, et al. Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc. 2016;5:e003048.
Segar MW, Khan MS, Patel KV, Vaduganathan M, Kannan V, Willett D, et al. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. Eur J Heart Fail. 2022;24:169-80.
Boonman-de Winter LJM, Rutten FH, Cramer MJ, Landman MJ, Zuithoff NPA, Liem AH, et al. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail. 2015;17:187-95.
TIMI Study Group. TIMI Risk Score for HF in Diabetes. https://timi.org/timi-risk-score-for-hf-in-diabetes/ (21 June 2022).
Resl M, Vila G, Heinzl M, Luger A, Neuhold S, Prager R, et al. Changes in the prognostic values of modern cardiovascular biomarkers in relation to duration of diabetes mellitus. J Diabetes Complications. 2021;35:107990.
Alonso N, Lupón J, Barallat J, de Antonio M, Domingo M, Zamora E, et al. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol. 2016;15:151.
Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21:40-9.
de Marco C, Claggett BL, de Denus S, Zile MR, Huynh T, Desai AS, et al. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Fail. 2021;8:1130-8.
Holmager P, Schou M, Egstrup M, Gustafsson I, Goetze JP, Gustafsson F, et al. The influence of diabetes mellitus on midregional proadrenomedullin concentrations and prognostic value in heart failure outpatients. J Card Fail. 2015;21:250-7.
Kistorp C, Chong AY, Gustafsson F, Galatius S, Raymond I, Faber J, et al. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail. 2008;10:380-7.
Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O'Connor CM, et al. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. Eur J Heart Fail. 2017;19:1310-20.
Cunha FM, Pereira J, Marques P, Moreira H, Rodrigues P, Pinto MJ, et al. Natriuretic peptide system activation in acute heart failure patients with diabetes. J Diabetes Res. 2017;2017:1426705.
Aspromonte N, Feola M, Milli M, Scardovi AB, Coletta C, Carbonieri E, et al. Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Diabet Med. 2007;24:124-30.